Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

Claim 1. (Currently Amended) A method for identifying a leukemia of T cell, B cell, or myeloid lineage in a <u>human subject</u>, said method comprising:

contacting a biological sample comprising leukocytes from the <u>human</u> subject with an array of immunoglobulin molecules immobilized to a solid support, <u>wherein the array comprises 7 to about 1000 immunoglobulins</u>, wherein the immunoglobulin molecules are specific for cell surface marker antigens, wherein the cell surface marker antigens comprise at least seven cell surface marker antigens selected from the list in Table 4, and wherein the cell surface marker antigens distinguish leukemias of T cell, B cell, or myeloid lineage; and

determining which cell surface marker antigens have bound to which immobilized immunoglobulin molecules to establish a differential pattern of density of binding that identifies a leukemia that is of T cell, B cell, or myeloid lineage.

Claim 2. (Previously Presented) The method of Claim 1, wherein the immunoglobulin molecules are monoclonal antibodies.

Claims 3. - 17. (Canceled)

Claim 18. (Previously Presented) The method of Claim 1 wherein the immunoglobulin molecules are polyclonal antibodies.

Claim 19. (Currently Amended) The method of Claim 1 wherein the biological sample is selected from the list consisting of eells, eell debris, eell extracts, tissue fluid, serum, plasma, blood, cerebrospinal fluid, urine, lymphatic fluid, seminal fluid, aspirate, bone marrow aspirate and mucus.

Application No. 09/888,959 Reply to Office Action dated November 23, 2005

Claim 20. (Previously Presented) The method of Claim 19 wherein the biological sample is blood.

Claim 21. (Previously Presented) The method of Claim 1, wherein the immunoglobulin molecules are antigen binding fragments of immunoglobulin molecules.

Claim 22. –23. (Canceled)